Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT4/LT3 combination therapy versus LT4 monotherapy for persistent tiredness in autoimmune hypothyroidism
2020-003214-12Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liothyronine and levothyroxine sodium in autoimmune thyroiditis, primary hypothyroidism (PH) and hypothyroidism (2 arms), sponsored by Erasmus MC. Primary endpoint: Mean change in ThyPRO tiredness subscale. Started Apr 2021; status: active.
02
Drugs
liothyroninelevothyroxine sodium
03
Conditions
autoimmune thyroiditisprimary hypothyroidism (PH)hypothyroidism
Beyond the preview
Go deeper on 2020-003214-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003214-12.